Two OTC CGMs Cleared; USPSTF Draft Recs for Osteoporosis; Generic Ozempic in Testing News and commentary from the endocrinology world Jun 11, 2024
Ozempic Price Cut; Hypoparathyroidism Tx Fast Tracked; Halle Berry's Menopause Bill News and commentary from the endocrinology world May 07, 2024
New T2D Guidelines; More Cushing's Relacorilant Data; Drug Shortages Rage On News and commentary from the endocrinology world Apr 23, 2024
Type D Personality and Hypothyroidism; Infertility and eGFR; Fracture Algorithm News and commentary from the endocrinology world Apr 09, 2024
FDA OKs First Interchangeable Biosimilars for Denosumab New products will carry all the same indications as Prolia and Xgeva, though launch date unclear Mar 06, 2024
Amy Schumer's Cushing's Dx; One Billion People With Obesity; Vitamin D for T1D News and commentary from the endocrinology world Mar 05, 2024
Clear Opportunity to Identify Patients With Osteoporosis Commonly Missed Hip surgeons could, but mostly don't, send at-risk patients for screening Feb 15, 2024
Denosumab Protective Against Diabetes? Study found lower diabetes incidence with osteoporosis drug for patients who stayed on treatment Feb 13, 2024
Insulin Discontinuation Tension; FDA OKs Osteopenia Belt; Limited Mounjaro Supply News and commentary from the endocrinology world Jan 30, 2024
Adults Who Cite Walking Difficulty Face Higher Fracture Risk Australian study suggests walking ability can help identify candidates for more assessment Jan 23, 2024
FDA Slaps Boxed Warning on Osteoporosis Drug Denosumab can cause severe hypocalcemia in patients with advanced CKD, agency finds Jan 19, 2024
Calcium Levels Quickly Become Critical for Many Denosumab-Treated Women on Dialysis New findings led to boxed warning on drug's labeling for advanced CKD patients Jan 19, 2024
Fracture Risk Bumped With Testosterone Therapy in Hypogonadal Men Researchers said this was not what they expected to find Jan 17, 2024
T1D Trial Paused After Deaths; Mounjaro Not Just Cosmetic; Late-Stage Hot Flash Win News and commentary from the endocrinology world Jan 09, 2024
Hibernating Squirrels for Obesity? Dialysis Warning; Endocrinology and Telehealth News and commentary from the endocrinology world Dec 26, 2023
New Diabetes Care Standards; Near 40% Ditch T2D Meds; Zepbound Hits Shelves News and commentary from the endocrinology world Dec 12, 2023
Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D News and commentary from the endocrinology world Dec 04, 2023
Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK'd News and commentary from the endocrinology world Nov 21, 2023
Farxiga Cuts A1c in Pediatric Diabetes; Late-Stage CAH Win; At-Home Menopause Test News and commentary from the endocrinology world Oct 10, 2023
Inflammation of the Aorta; Afib in the Hospital Also in TTHealthWatch: standards for osteoporosis screening and HbA1c in premenopausal women Oct 07, 2023 podcast
Postmenopausal Fracture Risk for SGLT2 Inhibitors Similar to Other Diabetes Drugs Lower risk compared with DPP-4 inhibitors, andΒ similar risk versus GLP-1 receptor agonists Sep 26, 2023
ENDO 2023 Roundup: More Imcivree Data; Statement on Aging; Novel Hypoparathyroid Tx Some more highlights from the Endocrine Society's annual meeting Jun 20, 2023
Oral Semaglutide Sheds Pounds; USPSTF Taking Obesity Comments; Plant Extract for T2D News and commentary from the endocrinology world May 23, 2023
Novel Hormone Replacer Holds Up Long-Term for Hypoparathyroidism But drug remains in regulatory limbo May 08, 2023
New Reader for FreeStyle Libre 3; COVID Bumps Diabetes Risk; Tepezza Label Expanded News and commentary from the endocrinology world Apr 18, 2023
Osteoporosis: Another Dementia Predictor? Low bone mineral density in certain places linked with dementia onset Mar 22, 2023
Dexcom G7 CGM Covered by Medicare; T1D Off-Label Drug Use; Another Tepezza Lawsuit News and commentary from the endocrinology world Feb 21, 2023
Rybelsus Now OK'd in First Line; Menopause Before Transition; Novel T2D Drug Flops News and commentary from the endocrinology world Jan 17, 2023
Higher BMI May Blunt Effects of Vitamin D Supplementation In VITAL study, lower increases in total 25-OHD levels seen for those with greater body weight Jan 17, 2023
New Hypercalcemia Guideline; Untreated Hyperparathyroidism Risky; PFAS Phase-Out News and commentary from the endocrinology world Dec 27, 2022
Watch for Severe Hypocalcemia in Dialysis Patients on Prolia, FDA Warns Agency said potential risk may require more frequent blood calcium monitoring Nov 22, 2022
One-Two Punch of Romosozumab, Denosumab Improved BMD and Reduced Fractures Taking the bone-forming agent followed by the antiresorptive was better than denosumab alone Sep 13, 2022
Novel Agent Hints at Bone Growth Boost Without Hematopoietic Risks Phase I study shows ability to modulate cell signaling Sep 13, 2022
Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer Areal BMD increased when given at the start of maximal estradiol depletion therapy Sep 13, 2022
Fish Oil Supplement Fails to Reduce Hip Fractures Further bad news for omega-3 fatty acids in VITAL trial analysis Sep 12, 2022
Cardiovascular Risks Not Increased With Denosumab Large observational databases mitigate concerns about the osteoporosis therapy Sep 12, 2022
Predicting Fractures in RA: Is FRAX Useful in the Modern Treatment Era? Algorithm held its own, but not many study patients were on biologics Sep 11, 2022
Good News, Bad News for Global Hip Fracture Rates Incidence has declined, but burden will increase as older population grows Sep 10, 2022
More Hip Fractures Seen in Women With This Diet Study compared vegetarian, pescatarian, and meat eaters Aug 11, 2022
Tymlos Boosts Bone Health in Men With Osteoporosis Daily agent upped bone mineral density at multiple sites in phase III ATOM trial May 14, 2022
